News

Novartis donates 250 000 TB treatments to the Stop TB Partnership


20 May 2010
by Working Group

Dr Klaus M Leisinger, President and Managing Director of the Novartis Foundation for Sustainable Development, and Dr Hiro Nakatani, WHO Assistant Director-General
Dr Klaus M Leisinger, President and Managing Director of the Novartis Foundation for Sustainable Development, and Dr Hiro Nakatani, WHO Assistant Director-General

Dr Klaus M Leisinger, President and Managing Director of the Novartis Foundation for Sustainable Development, and Dr Hiro Nakatani, WHO Assistant Director-General, yesterday signed a memorandum of understanding for the donation of 250 000 adult short-course TB treatments to the United Republic Tanzania through the Stop TB Partnership’s Global Drug Facility (GDF).

This agreement, which will run through 2012, is the extension of a 2005-2008 memorandum of understanding through which the Novartis foundation provided Tanzania and Sri Lanka with a total of 253 095 TB treatments, also delivered by GDF.

“Novartis is happy to continue its support to Tanzania’s very successful TB programme, with confidence that GDF will give the project the appropriate technical framework,” Dr Leisinger said. The Novartis foundation works closely with the Tanzanian National Tuberculosis Programme of the Tanzanian Ministry of Health and Social Welfare.

“We are grateful to Novartis and the Stop TB Partnership for supporting TB control in my country through this project, which will help us sustain the progress we have achieved,” said Prof David Mwakyusa, Minister of Health and Social Welfare of the United Republic of Tanzania.

Tanzania ranks 15th on the list of 22 high-burden TB countries in the world. Because of improved quality of services and evaluation, Tanzania has exceeded the Global Plan to Stop TB treatment success target of 85% since 2007.

“This agreement between Novartis, the Global Drug Facility and the government of the United Republic of Tanzania is an example of partnership at its best,” said Dr Marcos Espinal, Executive Secretary of the Stop TB Partnership. “We thank Novartis for this generous contribution and hope that others in the private sector will investigate innovative ways they can contribute to the global fight against TB.”

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...